东诚药业
(002675)
| 流通市值：100.88亿 | | | 总市值：111.90亿 |
| 流通股本：7.43亿 | | | 总股本：8.25亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,868,936,537.72 | 2,162,431,924.92 | 1,420,711,375.17 | 647,229,057.46 |
| 营业收入 | 2,868,936,537.72 | 2,162,431,924.92 | 1,420,711,375.17 | 647,229,057.46 |
| 二、营业总成本 | 2,649,051,861.74 | 1,945,421,595.59 | 1,264,859,468.07 | 597,994,534.45 |
| 营业成本 | 1,516,528,688.29 | 1,177,547,147.36 | 786,469,266.95 | 363,780,583.66 |
| 税金及附加 | 31,758,876.86 | 23,828,712.83 | 16,262,514.09 | 7,201,400.25 |
| 销售费用 | 414,767,086.97 | 313,371,279.06 | 201,431,813.92 | 103,237,681.29 |
| 管理费用 | 316,852,287.16 | 207,917,640.95 | 149,483,561.94 | 74,807,110.68 |
| 研发费用 | 291,911,236.55 | 153,887,901.66 | 90,923,023.63 | 45,209,265.3 |
| 财务费用 | 77,233,685.91 | 68,868,913.73 | 20,289,287.54 | 3,758,493.27 |
| 其中:利息费用 | 96,509,275.27 | 67,847,413.13 | 21,928,819.49 | 14,843,120.59 |
| 其中:利息收入 | 5,556,733.41 | 3,748,614.89 | 5,515,701.55 | 1,469,893.64 |
| 加:公允价值变动收益 | 1,068,427.73 | 579,593.75 | 240,753.42 | - |
| 加:投资收益 | -13,984,963.44 | -7,261,540.1 | -1,998,032.8 | 3,053,594.1 |
| 资产处置收益 | 302,727.5 | 82,076.79 | 65,276.9 | 77,337.46 |
| 资产减值损失(新) | -83,874,940.6 | 2,177,262.6 | 3,624,700.31 | 32,985,557.6 |
| 信用减值损失(新) | -17,461,644.59 | -12,312,806.46 | -12,650,412.23 | -5,399,108.54 |
| 其他收益 | 114,871,715.14 | 15,544,324.19 | 12,689,788.11 | 4,057,360.99 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 220,805,997.72 | 215,819,240.1 | 157,823,980.81 | 84,009,264.62 |
| 加:营业外收入 | 421,273.86 | 125,724.85 | 106,258.86 | 102,516.31 |
| 减:营业外支出 | 2,124,428.6 | 1,523,292.86 | 503,769.09 | 122,406.29 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 219,102,842.98 | 214,421,672.09 | 157,426,470.58 | 83,989,374.64 |
| 减:所得税费用 | 77,677,833.3 | 62,765,321.78 | 37,498,461.92 | 18,058,435.03 |
| 六、净利润 | 141,425,009.68 | 151,656,350.31 | 119,928,008.66 | 65,930,939.61 |
| 持续经营净利润 | 141,425,009.68 | 151,656,350.31 | 119,928,008.66 | 65,930,939.61 |
| 归属于母公司股东的净利润 | 183,825,711.34 | 166,868,105.35 | 111,789,792 | 64,327,510.75 |
| 少数股东损益 | -42,400,701.66 | -15,211,755.04 | 8,138,216.66 | 1,603,428.86 |
| (一)基本每股收益 | 0.22 | 0.2 | 0.14 | 0.08 |
| (二)稀释每股收益 | 0.22 | 0.2 | 0.14 | 0.08 |
| 八、其他综合收益 | 9,642,842.77 | 6,313,150.91 | -9,903,844.96 | -1,887,785.68 |
| 归属于母公司股东的其他综合收益 | 7,985,818.5 | 3,864,260.58 | -6,804,902.24 | -737,757.85 |
| 九、综合收益总额 | 151,067,852.45 | 157,969,501.22 | 110,024,163.7 | 64,043,153.93 |
| 归属于母公司股东的综合收益总额 | 191,811,529.84 | 170,732,365.93 | 104,984,889.76 | 63,589,752.9 |
| 归属于少数股东的综合收益总额 | -40,743,677.39 | -12,762,864.71 | 5,039,273.94 | 453,401.03 |
| 公告日期 | 2025-02-27 | 2024-10-29 | 2024-08-31 | 2024-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |